US FDA urged to revise or withdraw drug/device draft classification guides
This article was originally published in Clinica
Executive Summary
Two draft guidelines by the US Food and Drug Administration on classifying medical products as drugs or medical devices has drawn concern from stakeholders, who feel the documents could result in numerous products currently classified as medical devices having to be reclassified as drugs.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EMA Hopes New Requirement Will Make Companies Stick To Their Filing Plans
An additional form that marketing authorization applicants must now complete during the pre-submission stage emphasizes the importance of companies providing accurate information on their intended submission date.
EMA To Get The Ball Rolling On Making CTIS Global
The European Medicines Agency wants to further improve the visibility of data in the Clinical Trials Information System by establishing it as a World Health Organization primary registry.